Open Access 01-12-2012 | Research
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
Published in: Journal of Hematology & Oncology | Issue 1/2012
Login to get access